STAT+: At BIO, a glimpse behind Lilly and Chai’s partnership

STAT+ reported on a partnership between Eli Lilly and Chai during the BIO conference in San Diego. Regenxbio announced its intention to seek accelerated approval from the FDA for its gene therapy targeting Duchenne muscular dystrophy, signaling potential renewed FDA receptiveness to rare disease treatments. In parallel, ophthalmology startup Ollin Biosciences successfully secured $330 million in a Series B funding round, marking one of the largest such rounds for a biotech company in the past two years. This funding round highlights continued investor interest in specialized biotech ventures.